Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy

Journal of Allergy and Clinical Immunology

Volumn 98, Issue 1, 1996, Pages 1-13

  Holgate, Stephen T ^a   Bradding, Peter ^a   Sampson, Anthony P ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

5 lipoxygenase inhibitors; 5 lipoxygenase activating protein inhibitors; asthma; leukotriene B4 antagonists; leukotriene D4 antagonists; leukotrienes

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPYLTHIO]PHENYL] 4 HYDROXY 3 METHYLBUTYRIC ACID; 7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; ACEOLASE; ACETYLSALICYLIC ACID; ALLERGEN; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CROMOGLYCATE DISODIUM; DOCEBENONE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; PIRIPROST; POBILUKAST; PRANLUKAST; PROBILUKAST; SALBUTAMOL; THROMBOCYTE ACTIVATING FACTOR; TOMELUKAST; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; EXERCISE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0029739085     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(96)70220-8     Document Type: Article

References (89)

1. Barnes PJ. New aspects of asthma. J Intern Med 1992;231: 453-61.
2. Beasley R, Burgess C, Crane J, et al. Pathology of asthma and its clinical implications. J Allergy Clin Immunol 1993; 92:148-54.
3. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993;148:S1-S26.
4. Geddes D. Inhaled corticosteroids: benefits and risks. Thorax 1992;47:404-7.
5. Burney PGJ. Epidemiology of asthma. Br Med Bull 1992; 48:10-22.
6. Cockcroft DW. Practical issues in asthma management: correct use of inhalation devices. Ann Allergy 1993;71:83-4.
7. Chung KF, Barnes PJ. Role of inflammatory mediators in asthma. Br Med Bull 1992;48:135-48.
8. Samuelsson B. Leukotrienes: mediators of immediate hy persensitivity reactions and inflammation. Science 1983; 220:568-75.
9. Dixon RA, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990;343:282-4.
10. Chanarin N, Johnston SL. Leukotrienes as a target in asthma therapy. Drugs 1994;47:12-24.
11. Drazen JM. Leukotrienes in asthma and rhinitis. In: Busse W, Holgate ST, eds. Asthma and rhinitis. Oxford: Blackwell Scientific Publications, 1995:838-50.
12. Arm JP, Lee TH. Sulphidopeptide leukotrienes in asthma. Clin Sci (Colch) 1993;84:501-10.
13. Piacentini GL, Kaliner MA. The potential roles of leukotrienes in bronchial asthma. Am Rev Respir Dis 1991;143: S96-9.
14. 4 antagonists in anti-asthma trials: early promise for a single mediator antagonist. Pulmon Pharmacol 1992;5:77-80.
15. 4 effects on human eosinophil and neutrophil motility in vitro. J Leukoc Biol 1994;55:183-91.
16. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90.
17. 4. Am J Respir Cell Mol Biol 1993;8:493-9.
18. Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 1993;148:713-9.
19. Martin RJ, Cicutto LC, Smith HR, Ballard RD, Szefler SJ. Airways inflammation in nocturnal asthma. Am Rev Respir Dis 1991;143:351-7.
20. Sehmi R, Wardlaw AJ, Cromwell O, Kurihawa K, Waltmann P, Kay AB. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood 1992;79:2952-9.
21. 4 induces interleukin 5 generation from human T lymphocytes. Eur J Immunol 1993;23:2392-8.
22. Yamaoka KA, Dugas B, Paul-Eugene N, Mencia-Huerta JM, Braquet P, Kolb JP. Leukotriene B4 enhances IL-4-induced IgE production from normal human lymphocytes. Cell Immunol 1994;156:124-34.
23. Lam S, Chan H, LeRiche JC, Chan-Yeung M, Salari H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988;81:711-7.
24. 4 and 5-HETE by human alveolar macrophages in patients with asthma: effect in vitro of nedocromil sodium. Eur Respir J 1989;2:202-9.
25. Sampson AP, Thomas RU, Costello JF, Piper PJ. Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. Br J Clin Pharmacol 1992;33:423-30.
26. 4 generation by bronchoalveolar lavage cells in asthma. Thorax 1995;50:67-73.
27. Bjorck T, Dahlen SE. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. Pulmon Pharmacol 1993;6:87-96.
28. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am Rev Respir Dis 1990;142:112-9.
29. Dahlen S. Leukotrienes as mediators of airway obstruction and bronchial hyperresponsiveness. In: Page CP, Gardiner PJ, eds. Airway hyperresponsiveness: Is it really important for asthma? Oxford: Blackwell Scientific Publications, 1993: 188-205.
30. 4 after allergen challenge and in acute asthma and allergic rhinitis. Lancet 1989;1:584-8.
31. Sampson AP, Castling DP, Green CP, Hood PP, Piper PJ, Price JF. Leukotrienes in the blood and urine of children with acute asthma [abstract]. Am J Respir Crit Care Med 1994;149:A964.
32. 4-receptor antagonist improves pulmonary function in patients with mild chronic asthma. Am Rev Respir Dis 1989;140:1336-9.
33. Robuschi M, Riva E, Fuccella LM, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 1992;145:1285-8.
34. 4-receptor antagonist. N Engl J Med 1990;323:1736-9.
35. 4 receptor antagonist, in patients with chronic asthma [abstract]. J Allergy Clin Immunol 1991;87:309.
36. Krell RD, Aharony D, Buckner CK, et al. The preclinical pharmacology of ICI 204,219, a peptide leukotriene antagonist. Am Rev Respir Dis 1990;141:978-87.
37. Miyamoto T. The clinical evaluation of a leukotriene antagonist, ONO-1078. Presented at 15th European Congress of Allergology and Clinical Immunology; May 1992; Paris, France.
38. Fujimura M, Sakahato S, Kamis Y, Matsuda T. The effect of a leukotriene antagonist ONO 1078 on bronchial hyperresponsiveness in patients with asthma. Respir Med 1993; 87:133-8.
39. 4 in subjects with mild asthma. Br J Clin Pharmacol 1991;32:512-5.
40. 4 receptor antagonist [abstract]. Eur Respir J 1993;6:317s.
41. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990;141:988-92.
42. Smith LJ, Glass M, Minkwitz MC. Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther 1993;54:430-6.
43. 4 receptor antagonist. Am Rev Respir Dis 1992;145:746-9.
44. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993;147:1413-8.
45. 4 antagonist, inhibits exercise-induced bronchoconstriction in asthmatics at the end of a once daily dosing schedule [abstract]. Am J Respir Crit Care Med 1995;151:A377.
46. 4 receptor antagonist, ICI 204,219, on cold-air-induced bronchoconstriction in patients with asthma [abstract]. J Allergy Clin Immunol 1994;93:295.
47. 4 receptor antagonist ICI 204,219. J Allergy Clin Immunol 1993;147:215-7.
48. Montefort S, Gratziou C, Goulding D, et al. Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways. J Clin Invest 1994;93:1411-21.
49. Taniguchi Y, Tamura G, Honma M, et al. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol 1993;92:507-12.
50. 4 receptor antagonist, MK-571 [abstract]. Ann NY Acad Sci 1991;629:436.
51. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992;89:1040-5.
52. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of the cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337: 690-4.
53. Nathan RA, Glass M, Minkwitz MC. Inhaled ICI 204,219 blocks antigen-induced bronchoconstriction in subjects with bronchial asthma. Chest 1994;105:483-8.
54. 4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction. Am Rev Respir Dis 1993; 147:1431-5.
55. Calhoun WJ, Lavins BJ, Glass M. Effect of Accolate (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental antigen bronchoprovocation (SBP) in patients with mild to moderate asthma [abstract]. Am J Respir Crit Care Med 1995;151:A42.
56. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993;48:1205-10.
57. 4) antagonist (MK-571) in mild to moderate asthma [abstract]. J Allergy Clin Immunol 1990;85:197.
58. 4) receptor antagonist (MK-571) in patients with asthma. Am Rev Respir Dis 1992;146:358-63.
59. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991;337:1062-3.
60. 4 in asthmatics. Pulmon Pharmacol 1991;4:37-42.
61. Kips JC, Joos GF, Peleman RA, Pauwels RA. The effect of inhaled ICI 204,219 on baseline lung function in moderate asthma [abstract]. Am Rev Respir Dis 1993;147:A297.
62. 4 receptor antagonist, produces improvements in the signs and symptoms of asthma [abstract]. Eur Respir J 1994;7:282s.
63. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150:618-23.
64. Spector S, Miller CJ, Glass M. Thirteen-week dose-response study with Accolate (zafirlukast) in patients with mild to moderate asthma [abstract]. Am J Respir Crit Care Med 1995;151:A379.
65. Spector SL, Glass M, Minkwitz MC. The effect of six weeks therapy with oral doses of ICI 204,219 in asthmatics [abstract]. Am Rev Respir Dis 1992;145:A16.
66. Barnes NC, Pujet JC. First clinical experience of the oral leukotriene antagonist, pranlukast (SB205312 / ONO 1078) in N. European patients with mild to moderate asthma [abstract]. Am J Respir Crit Care Med 1995;151: A378.
67. 4 inhalation. Am Rev Respir Dis 1987;136:930-4.
68. 4 induces airway hyperresponsiveness in dogs. J Appl Physiol 1985;59:1941-6.
69. 4 antagonist, U-75,302, inhibits antigen-induced airway hyperresponsiveness but not leukocyte accumulation in sensitised guinea pigs [abstract]. Br J Pharmacol 1995;114:50P.
70. 4 to airway inflammation and the effect of antagonists. Ann NY Acad Sci 1991;629:274-87.
71. 4 receptor antagonist CP-105,696. J Pharmacol Exp Ther 1995;273:176-84.
72. Fuller RW, Maltby N, Richmond R, et al. Oral nafazatrom in man: effect on inhaled antigen challenge. Br J Clin Pharmacol 1987;23:677-81.
73. Mann JS, Holgate ST. Effect of piriprost (U-60,257) a novel leukotriene inhibitor on allergen- and exercise-induced asthma. Thorax 1986;41:746-52.
74. Fujimura M, Sasaki F, Nakatsumi Y, et al. Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. Thorax 1986; 41:955-65.
75. Cohn J. Zileuton (A-64077): a 5-lipoxygenase inhibitor. In: Lewis A, Furst DE, eds. Nonsteroidal anti-inflammatory drugs: mechanisms and clinical uses. 1994:367-90.
76. Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991;46:184-9.
77. Israel E, Demarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990;323:1740-4.
78. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148: 1447-51.
79. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-66.
80. Schwartz HJ, Petty T, Reed R, Dube LM, Swanson LJ, Zileuton Study Group. The comparative effects of zileuton, a 5-lipoxygenase inhibitor, vs. theophylline in patients with moderate asthma: results from a 13-week, multicenter trial [abstract]. Am J Respir Crit Care Med 1995;151:A376.
81. Liu M, Cohn J, Zileuton Study Group. Effects of zileuton, a 5-lipoxygenase inhibitor, in moderate asthma: results of a 6-month double-blind placebo-controlled trial [abstract]. Eur Respir J 1994;7:282s.
82. Israel E, Cohn J, Dube L, Drazen J, Zileuton Study Group. Chronic 5-lipoxygenase (5-LO) inhibition by zileuton significantly decreases the requirement for acute steroid treatment of asthma [abstract]. Am J Respir Crit Care Med 1995;151:A678.
83. Rosenberg MA, Torres MJ, Valencia A, et al. The effect of a 5-lipoxygenase (5-LO) inhibitor ABT-761 on inhaled house dust mite early asthmatic response. Presented at American Academy of Allergy and Immunology Annual Conference; February 24-March 1, 1995; New York, NY.
84. Strek ME, Solway J, Saller L, Kowash K, Miller CJ, Israel E. Effect of the 5-lipoxygenase inhibitor, ZD2138, on cold-air-induced bronchoconstriction in patients with asthma [abstract]. Am J Respir Crit Care Med 1995;151: A377.
85. 4. Proc Natl Acad Sci USA 1994;91: 7663-7.
86. Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993;147:839-44.
87. Diamant Z, Timmers MC, Van der Veen H, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995;95:42-51.
88. Storms W, Friedman BS, Zhang J, et al. Treating asthma by blocking the lipoxygenase pathway [abstract]. Am J Respir Cell Mol Biol 1995;151:A377.
89. Virchow JC, Noller PS, Wiessman KJ, et al. Multicenter trial of Bay x1005, a new 5-lipoxygenase activating protein inhibitor in the treatment of chronic asthma [abstract]. Am J Respir Crit Care Med 1995;151:A377.